- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research term ...

Decibel Visual Journalist Joe Rocha discusses his favorite project of 2021. To ring in the new year, Team Decibel is sharing their favorite stories of 2021. Decibel Executive Editor Samantha Guzman ...

Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add this ...

– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D ...